Inflammatory Breast Cancer Research Foundation

Questions About the Clinical Treatment of IBC

What does the medical/health condition of those 5 or more years from diagnosis of IBC reveal? To what degree can current health conditions be attributed to prior treatment for IBC?
What is the benefit of including anti-angiogenesis treatment with induction chemotherapy? see VEGF-C, VEGF-D and VEGFR-3 in Tumor Angiogenesis, Lymphangiogenesis and Metastasis and Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.
When is there going to be a clinical trial for IBC patients using a Farnesyltransferase Inhibitor? see Prenylation of Proteins, Farnesyltransferase inhibitors: mechanism and applications, and RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.
What does the analysis of results of 50 to 300 autopsies of IBC patients reveal?

up to content »

Shopping Cart

Your shopping cart is empty.
Visit the shop